久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

  Home>News Center>Life
         
 

Chinese firm develops gene therapy injection
(China Daily)
Updated: 2004-03-23 08:56

Two months ago, China's State Food and Drug Administration (SFDA) issued its approval allowing Shenzhen-based SiBiono Gene Technology Co Ltd to produce its gene therapy medication.

The SFDA's approval enables SiBiono to become the first company in the world to produce a licensed gene therapy medication.

And SFDA's decision followed its own authorization last October, of the official licence granted to the same company to conduct clinical gene therapy trials in China.

The official approval has given Peng Zhaohui, 55, chairman and CEO of Shenzhen SiBiono Gene Technology Co Ltd, and his colleagues additional confidence in their pursuit for better remedies for illnesses that harm and kill a lot of people every year.

"Although we have developed the world's first commercial gene therapy medicine, there are still a lot of things unknown in the field," said Peng in an exclusive interview with China Daily.

"But we have the confidence to work on and unravel more of the mysteries," he said.

Road to Gendicine

Peng began to learn about gene therapy during his doctoral studies in Japan in the late 1980s.

Genes are the basic physical and functional units of heredity and they are carried on chromosomes.

Genes have specific sequences of bases that encode instructions on how to make proteins, which perform most life functions and even make up the majority of cellular structures.

Genetic disorders result when genes are altered and encoded proteins are unable to carry out their normal functions.

Researchers began to look into gene therapy in the late 1980s to develop techniques for correcting defective genes responsible for disease development.

For instance, they believe they can use new genes to stall the gene expression of defective target cells, such as cancer cells, and hence curb their natural reproduction.

After finishing his doctoral programme, Peng chaired a biological chemistry lab in Guangzhou, in South China's Guangdong Province, and led a research team into the vast, unknown but promising ocean of gene therapy.

Gene therapy theory and practice were widely proposed in the United States and western Europe, and limited clinical trials started in the early 1990s. In China, Peng and other researchers scoured current medical literature to explore the pioneering field.

Theoretical fruits came first. In 1994 he published China's first book on gene therapy.

Yet in practice his team was frustrated again and again. "Although we had a sufficient grasp of the theories, we did not have a good grasp of the processing techniques," he recalled. "Our preparation was not yet adequate."

He pointed out that placing more importance on theories and not paying enough attention to processing techniques and quality control is a common shortcoming among Chinese biological researchers.

But Peng and his colleagues did not give up.

"More than 50 per cent of major human diseases are believed to be linked to decaying or disordered human genes. I believe gene therapy will definitely play a leading role in medical science in China in the future," Peng said.

In 1994 he went to do further research in the United States. There Peng furthered his understanding of biological processing and quality control techniques.

But conducting research in the United States was not enough for Peng, because there he could not start work on what he wanted to do most - develop a gene therapy medicine.

In late 1997, Peng returned China and soon established his SiBiono company to develop his gene therapy medicine - Recombinant Ad-p53 Anti-cancer Injection, later registered as Gendicine.

"We were all touched by Peng's enthusiasm and his devotion to developing gene therapy. As a result, our local government decided to support his programme as much as possible," said Zhou Hui, deputy director of the Bureau of Science and Technology of Shenzhen's Nanshan District.

SiBiono is located in Shenzhen's Nanshan High-tech Zone.

Gendicine uses an adenoviral vector to carry p53 tumour suppressor genes to tumour cells. It is widely believed that P53 is the most powerful gene known to curb the genetic expression of tumour cells.

By the time Peng established SiBiono, more than 600 gene therapy plans had been launched in the United States, Europe and Japan.

But the research involved was tortuous.

In the United States, the clinical trial of a leading gene therapy product was suspended in 2000, because of its strong side effects. Progress in Europe has also been slow and has experienced similar setbacks.

Well aware of the difficulties, Peng and his colleagues continued their work.

They started with the careful choice of what they thought would be the right vector, proper target diseases and careful dosages of the injection.

They chose head and neck squamous cell carcinoma, the second most common skin cancer after basal cell carcinoma, for the test. Of the 2.5 million Chinese diagnosed with cancer every year, about 250,000 have squamous cell cancer.

The low clinical costs in China meant that SiBiono could conduct more than five years of clinical trials without facing any serious financial problems.

In the United States, the average cost incurred per patient during clinical trials is about US$50,000. Peng said that Gendicine's trials cost only a tiny portion of that sum.

Government support was another advantage for Gendicine.

Peng estimates the total investment in Gendicine at about 80 million yuan (US$9.66 million), one fourth of which came from various government sources, including the Ministry of Science and Technology, the 863 programme - a State high-tech fund, and the Shenzhen municipal government.

Investors from China's Tsinghua University-affiliated enterprises have consistently supported the Gendicine programme.

"Yet without Peng's persistence, all the advantages would not have played their due role," said Zhou, who has been close to Peng's programme since its beginning.

Deep roots

Peng's determined resolve and his diligence have deep roots.

Peng obtained his preliminary medical knowledge in a one-year training class in his rural hometown in Northwest China's Shaanxi Province at the age of 14.

The class ended with the beginning of the "cultural revolution" (1966-76), but Peng had to look after the pharmacy of a rural hospital because all the regular doctors and apothecaries were forced to stop their daily work and get involved in the political movement. Some of them were even persecuted.

"At that time I had to study medical texts night after night to deal with the work in the pharmacy. I even developed some special remedies to ease my patients medical problems," Peng said.

In 1970, Peng joined the army, serving on the Qinghai-Tibet Plateau. As a result of his good work, he was recommended for study in a Guangzhou-based medical college two years later.

"In such a harsh environment as that of the plateau, one could only do two things: struggle to survive in the harsh natural environment and try to help others survive," Peng said. "That's why I insisted on developing Gendicine no matter how many difficulties we met."

In 1998, Peng and his team prepared a 1,000-page Chinese report and a 1,300-page English version of it to apply for the clinical trial of the gene therapy medicine.

Their hardwork amazed the experts with the then State Drug Administration (SDA), which became the State Food and Drug Administration in 2003.

The SDA approval for clinical trial was issued, but some hospitals and doctors were reluctant to help Peng carry out the clinical trial of the drug.

It was indeed risky.

Peng and his colleagues worked hard to persuade hospitals and doctors one by one.

Peng and the other doctors leading the clinical trial discussed each treatment plan to ensure the patients' safety.

The ceaseless efforts paid off.

The clinical trial showed that after eight weeks of therapy involving one injection per week, 64 per cent of patients' tumours saw complete regression and 32 per cent experienced partial regression.

A total of 107 patients are involved in clinical trial II, and the statistics are based on clinical trial II's data. A third clinical trial is no longer required by the SFDA.

In combination with chemo- and radiotherapy, Gendicine improved treatment efficacy more than 3-fold, according to Professor Zhang Shanwen of Beijing Cancer Hospital, affiliated with Peking University, who chairs Gendicine's clinical trial II.

But Peng had another challenge to face.

Industry insiders say that in practice, the SFDA routinely does not approve any new kind of medicine if a medicine of that kind has not already been authorized by the US Food and Drug Administration.

"Our strategy of choosing a type of squamous, or skin, cancer as a target disease has helped," Peng said.

The large proportion of skin cancer patients in China has made it easier for the drug authorities to make the decision.

"While one significance of Gendicine is its ability to save thousands of lives, another significance of the drug is that it has proven that we are not behind the rest of the world and that we can become a world leader if we work hard enough," Peng said.

How gene therapy works

In most gene therapy studies, a "normal" gene is inserted into the genome to replace an "abnormal," disease-causing gene. A carrier molecule called a vector must be used to deliver the therapeutic gene to the patient's target cells.

Currently, the most common vector is a virus that has been genetically altered to carry normal human DNA.

Viruses have evolved a way of encapsulating and delivering their genes to human cells in a pathogenic manner.

Scientists have tried to take advantage of this capability and manipulate the virus genome to remove disease-causing genes and insert therapeutic genes.

Target cells such as the patient's liver or lung cells are infected with the viral vector. The vector then unloads its genetic material containing the therapeutic human gene into the target cell.

The generation of a functional protein product from the therapeutic gene restores the target cell to a normal state.

Some of the different types of viruses used as gene therapy vectors:

Retroviruses - A class of viruses that can create double-stranded DNA copies of their RNA genomes. These copies of its genome can be integrated into the chromosomes of host cells. Human immunodeficiency virus (HIV) is a retrovirus.

Adenoviruses - A class of viruses with double-stranded DNA genomes that cause respiratory, intestinal, and eye infections in humans. The virus that causes the common cold is an adenovirus.

Adeno-associated viruses - A class of small, single-stranded DNA viruses that can insert their genetic material at a specific site on chromosome 19.

Herpes simplex viruses - A class of double-stranded DNA viruses that infect a particular cell type, neurons. Herpes simplex virus type 1 is a common human pathogen that causes cold sores.

In addition to virus-mediated gene-delivery systems, there are several nonviral options for gene delivery. The simplest method is the direct introduction of therapeutic DNA into target cells. This approach is limited in its application because it can be used only with certain tissues and requires large amounts of DNA.

Current status of research

The United States Food and Drug Administration (FDA) has not yet approved any human gene therapy product for sale.

Current gene therapy is experimental and has not proven very successful in clinical trials. Little progress has been made since the first gene therapy clinical trial began in 1990.

In 1999, gene therapy suffered a major setback with the death of 18-year-old Jesse Gelsinger. Gelsinger was participating in a gene therapy trial for ornithine transcarboxylase deficiency (OTCD). He died from multiple organ failures four days after starting the treatment. His death is believed to have been triggered by a severe immune response to the adenovirus carrier.

Another major blow came in January 2003, when the USFDA placed a temporary halt on all gene therapy trials using retroviral vectors in blood stem cells. USFDA took this action after it learned that a second child treated in a French gene therapy trial had developed a leukemia-like condition. Both this child and another who had developed a similar condition in August 2002 had been successfully treated by gene therapy for X-linked severe combined immunodeficiency disease (X-SCID), also known as "bubble baby syndrome."

Factors keeping it from becoming effective treatment

The short-lived nature of gene therapy: Before gene therapy can become a permanent cure for any condition, the therapeutic DNA introduced into target cells must remain functional and the cells containing the therapeutic DNA must be long-lived and stable.

Problems with integrating therapeutic DNA into the genome and the rapidly dividing nature of many cells prevent gene therapy from achieving any long-term benefits. Patients will have to undergo multiple rounds of gene therapy.

Immune response: Anytime a foreign object is introduced into human tissues, the immune system is designed to attack the invader. The risk of stimulating the immune system in a way that reduces gene therapy effectiveness is always a potential risk. Furthermore, the immune system's enhanced response to invaders it has seen before makes it difficult for gene therapy to be repeated in patients.

Problems with viral vectors: Viruses, while the carrier of choice in most gene therapy studies, present a variety of potential problems to the patient - toxicity, immune and inflammatory responses, and gene control and targeting issues. In addition, there is always the fear that the viral vector, once inside the patient, may recover its ability to cause disease.

Multigene disorders: Conditions or disorders that arise from mutations in a single gene are the best candidates for gene therapy.

Unfortunately, some the most commonly occurring disorders, such as heart disease, high blood pressure, Alzheimer's disease, arthritis, and diabetes, are caused by the combined effects of variations in many genes.

Multigene or multifactorial disorders such as these would be especially difficult to treat effectively using gene therapy.

 
  Today's Top News     Top Life News
 

Government puts lid on overheating industries

 

   
 

Yassin buried; Hamas pledges retaliation

 

   
 

Chinese cities preparing emergency plans

 

   
 

Oil price hike not to force up airfares

 

   
 

Nationwide campaign against sea misuse

 

   
 

"Golden Week" Europe trip still out of reach

 

   
  Chinese firm develops gene therapy injection
   
  Woman tractor driver breaks new ground
   
  China vows to raise moral standards of young people
   
  4000 year-old city excavated in Central China
   
  Janet Jackson hails Her fortitude at awards show
   
  Albino micro-bat
   
 
  Go to Another Section  
 
 
  Story Tools  
   
  Related Stories  
   
Officials assure gene-altered crops are safe
   
China OKs import of 5 genetically modified crops
   
Gene map of Chimpanzee published
   
Obesity gene discovery will 'revolutionise treatment'
   
UK gene crop test results fuel demands for ban
  Feature  
  HK pop star Edison Chen punched by youngsters  
Advertisement
         
久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    男人天堂av片| 日韩精品视频久久| 成人三级视频在线播放| 国产精品999.| 日韩av在线第一页| 久久99国产精品一区| 亚洲一区二区蜜桃| 亚洲国产精品无码观看久久| 在线观看免费的av| 欧美 丝袜 自拍 制服 另类| 天天做天天爱天天高潮| www.日日操| 日韩精品视频在线观看视频| 在线播放av中文字幕| 国产又大又硬又粗| 欧美黄网在线观看| 四虎成人在线播放| 美女黄色片视频| 国产av麻豆mag剧集| 国产免费一区二区三区四在线播放 | 国产成人精品视频免费看| 国产高清精品软男同| 亚洲成人av免费看| 亚洲欧洲日产国码无码久久99| 国产精品啪啪啪视频| 999这里有精品| 亚洲色图38p| 国产精品秘入口18禁麻豆免会员| 九一免费在线观看| 青娱乐国产精品视频| 免费看污污网站| 激情网站五月天| 中文字幕日本最新乱码视频| 欧美一级免费播放| 波多野结衣av一区二区全免费观看| 91aaa精品| 黄色小视频免费网站| 国产成人av影视| 97在线免费公开视频| 黄色大片在线免费看| 成人在线观看a| 国产极品尤物在线| 国产乱子伦农村叉叉叉| 国产黄色激情视频| 菠萝蜜视频在线观看入口| 欧美一级黄色录像片| 桥本有菜av在线| 日本黄xxxxxxxxx100| 国产高清av片| 吴梦梦av在线| 999久久久精品视频| 在线一区二区不卡| 国产又黄又猛又粗| 五月天av在线播放| 亚洲精品在线视频播放| 国产精品99久久久久久大便| 青少年xxxxx性开放hg| 日韩视频一二三| 久操手机在线视频| 日本中文字幕网址| 午夜肉伦伦影院| 中文字幕国产传媒| 日韩欧美理论片| 只有这里有精品| 草草草视频在线观看| 免费一级特黄特色毛片久久看| 国产精品后入内射日本在线观看| 97av视频在线观看| 黄色国产小视频| 九九精品久久久| 樱空桃在线播放| 成人性生活视频免费看| 日本免费一级视频| av免费一区二区| 天天综合五月天| 激情六月天婷婷| 欧美成人一区二区在线观看| 爱情岛论坛vip永久入口| 一级淫片在线观看| 免费观看黄色大片| 久久综合色视频| 日韩精品一区二区三区不卡| 嫩草视频免费在线观看| 黑人巨茎大战欧美白妇| 国产二级片在线观看| caoporn超碰97| 国产手机视频在线观看| 国产91在线免费| 午夜剧场在线免费观看| 白白操在线视频| 欧美黄色一级片视频| 精品一区二区成人免费视频| 午夜免费福利小电影| 成人日韩在线视频| 69sex久久精品国产麻豆| 五月婷婷丁香综合网| 国产激情片在线观看| 免费大片在线观看| 大桥未久一区二区三区| 亚洲自偷自拍熟女另类| 亚洲视频在线不卡| www.中文字幕在线| 91香蕉视频网址| 十八禁视频网站在线观看| 天天干天天操天天干天天操| av黄色在线网站| 夜夜爽久久精品91| 男人天堂成人在线| 日韩精品一区二区在线视频 | 日本成人性视频| 国产男女无遮挡| 欧美日韩一区二区三区电影| 老头吃奶性行交视频| 日本丰满大乳奶| 国产精品一区二区羞羞答答| 久久久久久人妻一区二区三区| 日本一二区免费| 日本一区二区黄色| 日本中文字幕一级片| 日本中文字幕观看| 欧美日韩亚洲第一| 日韩精品久久一区二区| 日韩va在线观看| 国语对白做受xxxxx在线中国| 成年丰满熟妇午夜免费视频| 三级av免费观看| 欧美深夜福利视频| 亚洲精品国产suv一区88| 亚洲一级片av| 国产v亚洲v天堂无码久久久| 国产在线xxxx| 艳母动漫在线免费观看| 美女在线视频一区二区| 久久精品99国产| 久草视频国产在线| 久久久久久久久影视| 亚洲三级视频网站| 欧美xxxx吸乳| 北条麻妃av高潮尖叫在线观看| 乱妇乱女熟妇熟女网站| 国产天堂视频在线观看| a级网站在线观看| 手机福利在线视频| 粉嫩虎白女毛片人体| 欧美一区二区三区爽大粗免费| 欧美亚洲黄色片| 欧美视频在线第一页| 国产专区在线视频| eeuss中文| 色中文字幕在线观看| 手机精品视频在线| 永久免费黄色片| 亚洲精品mv在线观看| 蜜桃福利午夜精品一区| 日韩一级片免费视频| avove在线观看| 免费的av在线| 国产成人亚洲综合无码| 亚洲精品国产suv一区88| 无码人妻精品一区二区三区99v| 色乱码一区二区三区熟女 | 国产欧美综合一区| 91视频福利网| 免费成人深夜夜行网站视频| 黄色网址在线免费看| 福利在线小视频| 免费看日本黄色| 国产精品国产亚洲精品看不卡| 中文字幕无码精品亚洲资源网久久| 国产九色porny| 国产黄页在线观看| 免费在线观看毛片网站| 精品久久久噜噜噜噜久久图片| 亚洲黄色小视频在线观看| 99热手机在线| 在线免费观看av网| 欧美做暖暖视频| 水蜜桃色314在线观看| 超碰97人人射妻| 超碰在线97免费| 国内av免费观看| 97中文字幕在线| 色欲av无码一区二区人妻| 午夜激情福利在线| 国产资源中文字幕| 国产 欧美 日韩 一区| 91精品91久久久中77777老牛| 爱情岛论坛vip永久入口| 日韩va在线观看| 一区二区三区日韩视频| a级黄色小视频| 美女网站免费观看视频| 欧美精品色视频| 精品少妇人欧美激情在线观看| 漂亮人妻被中出中文字幕| 性欧美1819| 国产欧美精品aaaaaa片| 久久久久国产精品熟女影院| 韩国一区二区在线播放| 九一国产精品视频|